Animal-free cell therapy from Aachen secures global growth

PL BioScience closes Series A financing in the amount of 7.8 million euros

09-Aug-2024
PL BioScience GmbH

The demand for safe and effective cell culture media for therapeutic development is increasing rapidly.

PL BioScience GmbH has successfully completed a Series A financing round. The growth financing round attracted significant investments from AVANT BIO (New York), LePure Biotech (Shanghai), b.value AG (Dortmund) and better ventures (Munich). The four partners contribute their experience in deep tech, life sciences and health tech. The consortium joins a group of existing investors led by Brightlands Venture Partners (Geleen) and TechVision Fonds (Aachen), who have once again pledged their support for the Aachen-based biotech company's mission. PL BioScience's Human Platelet Lysate (HPL) technology enables breakthrough developments in cell therapy.

"We look forward to continuing our support for PL BioScience and its outstanding HPL products in the coming years together with this great consortium of investors," says Bernhard Kugel, Managing Partner of the TechVision Fund. Dr. Luc Starmans, Partner at Brightlands Venture Partners, also expresses his continued commitment: "We warmly congratulate the team and welcome our new partners on this exciting journey. Together, we look forward to building on PL BioScience's groundbreaking work to advance effective cell therapies that will bring transformative benefits to both patients and the planet."

Pioneering cell culture technology from Aachen

HPL is derived from donated blood that is no longer suitable for transfusion and offers a sustainable and effective alternative to animal-derived cell culture media. Conventional methods often use fetal calf serum (TCS), which is obtained from the blood of calf fetuses. With HPL, a more seamless transferability of research results to humans is possible. The technology ensures reliable results in laboratories worldwide, paving the way for major advances in regenerative medicine.

Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.

See the theme worlds for related content

Topic world Cell culture technology

Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.

3 whitepaper
View topic world
Topic world Cell culture technology

Topic world Cell culture technology

Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.

3 whitepaper